Janeen Noel Doyle - 02 Jan 2026 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Corp. & Bus. Dev. Ofcr
Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
02 Jan 2026, 21:00:09 UTC
Previous filing
04 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO /s/ James Pennington, Attorney-in-Fact 02 Jan 2026 0002069239

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +36,000 +82% $0.000000 80,000 02 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock option (right to buy) Award $0 +126,000 $0.000000 126,000 02 Jan 2026 Common Stock 126,000 $13.65 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
F2 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.